The US FDA has granted accelerated approval to asciminib, a tyrosine kinase inhibitor, for treating adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia. Clinical evidence In a clinical trial conducted on 405 patients, asciminib demonstrated superior efficacy over currently available tyrosine kinase inhibitors, including imatinib, nilotinib, dasatinib, and bosutinib, by achieving higher major molecular response at 48 weeks (68% vs.
49%). Dosage and administration Available as film-coated tablets (20 mg, 40 mg, and 100 mg) 40 mg orally twice daily or 80 mg orally once daily Warnings and precautions Myelosuppression Pancreatic toxicity Hypertension Hypersensitivity Cardiovascular toxicity Embryo-fetal toxicity Adverse reactions – Musculoskeletal pain, abdominal pain, rash, diarrhea, fatigue, headache, and upper respiratory tract infection Did you…
